Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease
NCT02908815, Not applicable, Completed, University of Manitoba
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT02908815 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 200 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Manitoba | ClinicalTrials.gov |
| Conditions | Alzheimer's Disease | ClinicalTrials.gov |
| Interventions | rTMS active treatment, rTMS sham treatment | ClinicalTrials.gov |
| First posted | 2016-09-21 | ClinicalTrials.gov |
| Last updated | 2024-06-28 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) change | Weeks 0 and 5 | Standard measure of cognitive symptoms, a popular tool that measures the severity of dementia symptoms. The primary outcome measure will be the change in the score from the baseline at 5 weeks. | ClinicalTrials.gov |
| Secondary | Stroop Test | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Measures a person's attention by having them read colour names when the colour of the text doesn't match. | ClinicalTrials.gov |
| Secondary | Digit Span Test | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Memory test asking the participant to remember a sequence of numbers and repeat them back. | ClinicalTrials.gov |
| Secondary | Verbal Fluency Test (VFT) | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Fluency test where the participant has to name as many words a possible that match a certain criteria. | ClinicalTrials.gov |
| Secondary | Neuropsychiatric Inventory-Questionnaire (NPI-Q) | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Caregiver questionnaire that assesses severity of symptoms | ClinicalTrials.gov |
| Secondary | Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Caregiver questionnaire that assesses patient's ability to handle daily activities | ClinicalTrials.gov |
| Secondary | Zarit Burden Interview (ZBI) | Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Caregiver questionnaire that assesses the burden of the patient on the caregiver | ClinicalTrials.gov |
| Secondary | Treatment Satisfaction Questionnaire for Medication (TSQM) | Weeks 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups | Assessment that asks directly if the participant is satisfied with the treatment | ClinicalTrials.gov |
| Secondary | Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) effect over time | Weeks 0, 3, 11, 19, and 27 for the 2 week group and weeks 0, 3, 13, 21, and 29 for the 4 week groups | Standard measure of cognitive symptoms, a popular tool that measures the severity of dementia symptoms. | ClinicalTrials.gov |
| Secondary | Semantic Fluency Test (SFT) | Before and immediately after rTMS intervention in Week 1, at weeks 5 and 11 for the 2 week group and before and immediately after rTMS intervention in Week 1, at weeks 5, and 13 for the 4 week groups | Fluency test where the participant has to name as many animals in 1 minute (Winnipeg and Montreal sites only) | ClinicalTrials.gov |
| Secondary | Clinical Dementia Rating (CDR) sum of boxes | Week 27 for the 2 week group and week 29 for the 4 week group | Assesses the severity of cognitive and functional decline related to Alzheimer's disease and other dementias | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)